Sophia Genetics 2026 guidance points to faster growth and leverage
SOPHiA GENETICS fiscal Q4 2025 revenue up 22% to $21.7M, beats estimates, EPS misses, 2026 guidance points to faster growth and leverage
- Q4 revenue grew 22% to $21.7M; full-year 2025 revenue rose 19% to $77.3M.
- Q4 non-GAAP EPS was $-0.28 (-22% YoY), missing estimates even as revenue beat expectations.
- Clinical revenue ex-biopharma grew 31% in Q4, with U.S. analysis volumes up ~50%.
- 2026 revenue guided to $92–94M, implying 20–22% growth and back-half weighting.
- 2026 adjusted EBITDA loss guided to $29–32M vs $41.5M in 2025, showing strong leverage.
- Adjusted gross margin expanded 140 bps in 2025 to 74.2% despite nearly doubling data processed.
- Net dollar retention improved to 115% with churn below 1%, highlighting strong stickiness and upsell.
- Record 124 new customers signed in 2025; average contract value rose 120% year-over-year.
- Biopharma momentum improving with renewed AstraZeneca deal and new global top-5 pharma agreement.
- Cash burn improved to $50.4M; liquidity bolstered by $15.5M ATM raise and $25M credit expansion.
- CEO transition to Ross Muken in July 2026 adds execution focus as company targets profitability by 2027.
- Main concern: sustaining growth and funding amid ongoing cash burn, FX headwinds, and long biopharma ramp times.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.